Bisphosphonates vs Denosumab vs Romosozumab: Honest Comparison
Three classes of medication dominate osteoporosis treatment in 2026: bisphosphonates (first-line for decades), denosumab (RANK-ligand inhibitor), and romosozumab (sclerostin inhibitor, newer). Each has clear advantages and trade-offs. This piece walks through the comparison your specialist would have if they had 60 minutes per appointment.
Bisphosphonates: the workhorse
Alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), zoledronate (Reclast/IV). Cost: cheap, often generic. Dosing: weekly or monthly oral, or yearly IV. Efficacy: ~50% reduction in vertebral fracture, 25-40% in non-vertebral over 3-5 years. Side effects: oesophageal irritation (oral), flu-like response (IV first dose), rare ONJ and atypical femur fracture at long use. Best for: most first-line cases, particularly with moderate fracture risk.
Denosumab: the steady option
Marketed as Prolia. Cost: more expensive than generic bisphosphonates. Dosing: subcutaneous injection every 6 months — convenient. Efficacy: ~68% reduction in vertebral fracture, 40% non-vertebral. Side effects: similar to bisphosphonates plus increased infection risk in some patients. Critical caveat: stopping denosumab without transition produces rapid bone loss and fracture rebound; you cannot just “take a break.” Must be followed by bisphosphonate or alternative. Best for: bisphosphonate-intolerant patients, kidney disease (bisphosphonates excrete renally).
Romosozumab: the newer entrant
Marketed as Evenity. Cost: substantially more expensive. Dosing: monthly subcutaneous injection for 12 months only. Efficacy: largest T-score gain of the three (5-7% at lumbar spine in 12 months). Side effects: cardiovascular warning — increased MACE in some trials. Best for: severe osteoporosis with high fracture risk and no cardiovascular contraindication. Used as 12-month course, then transitioned to bisphosphonate or denosumab for maintenance.
How they get sequenced in clinical practice
Standard sequence in moderate-risk cases: bisphosphonate 3-5 years, drug holiday if T-score improved, reassess. High-risk or fracture-failure: switch to denosumab or romosozumab. Severe with prior fragility fracture or T-score below -3.0 with risk factors: consider romosozumab first, transition to denosumab/bisphosphonate. Order matters because romosozumab works best in treatment-naive bone tissue.
The lifestyle pillars still apply
No medication replaces loaded exercise, K2, magnesium, vitamin D and protein. Combination produces better outcomes than medication alone in every published trial. The four-pillar protocol is the foundation regardless of which medication class is added on top, and packaged versions of it exist — our breakdown of a non-drug bone routine covers one — but they sit alongside a prescribed medication, not instead of it.
FAQ
Can I switch between medications?
Yes, but transitions must be supervised — particularly denosumab discontinuation needs a bisphosphonate bridge.
How do I know which is right for me?
Specialist (endocrinologist or rheumatologist) consultation. FRAX score, prior fractures, kidney function, cardiovascular status all matter.
Are there non-injection options for severe osteoporosis?
Oral bisphosphonates only. For severe cases, the injectable options have generally better outcomes per dollar.
Is there anything for people who refuse all medication?
Yes — the natural protocol (loaded exercise + nutrient stack + protein + sleep). Less powerful than medication for moderate-to-severe cases but the right primary approach for borderline T-scores.
